Valuation: AstraZeneca PLC

Market Cap 246B 220B 204B 186B 351B 23,820B 353B 2,461B 963B 12,130B 925B 904B 38,969B P/E 2026 *
20.6x
P/E 2027 * 17.6x
Enterprise Value 266B 238B 221B 201B 380B 25,759B 381B 2,661B 1,041B 13,118B 1T 978B 42,141B EV / Sales 2026 *
4.21x
EV / Sales 2027 * 3.85x
Free-Float
96.62%
Yield 2026 *
2.1%
Yield 2027 * 2.23%
1 day+1.08%
1 week+1.11%
Current month-2.57%
1 month+4.77%
3 months-6.98%
6 months-16.15%
Current year-6.57%
1 week 1,556
Extreme 1556
1,610
1 month 1,535.5
Extreme 1535.5
1,689
Current year 1,467
Extreme 1467
1,925.5
1 year 1,467
Extreme 1467
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 978.1
Extreme 978.1
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Chief Operating Officer 55 31/05/2015
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+1.11% - - 246B
+0.83%+3.19%+37.87%+106.25% 1,051B
+1.93%+2.11%+36.82%+64.90% 630B
+1.49%+5.19%+19.84%+85.41% 489B
+2.26%+0.90%+66.40%+39.33% 359B
+1.45%+3.50%+21.87%+42.64% 344B
+1.17%+2.37%+11.71%+35.14% 272B
+0.89%+1.08%-7.28%+10.52% 246B
+1.82%+2.94%+40.43%+52.78% 224B
+2.77%+4.44%+29.49%+101.40% 187B
Average +1.57%+2.53%+28.57%+59.82% 422.63B
Weighted average by Cap. +1.45%+2.44%+31.57%+69.97%

Financials

2026 *2027 *
Net sales 63.33B 56.54B 52.56B 47.86B 90.27B 6,126B 90.7B 633B 248B 3,119B 238B 233B 10,021B 67.21B 60B 55.78B 50.8B 95.8B 6,501B 96.26B 672B 263B 3,311B 252B 247B 10,635B
Net income 11.9B 10.62B 9.88B 8.99B 16.96B 1,151B 17.04B 119B 46.51B 586B 44.69B 43.71B 1,883B 13.84B 12.35B 11.49B 10.46B 19.72B 1,339B 19.82B 138B 54.09B 682B 51.96B 50.82B 2,190B
Net Debt 20.05B 17.9B 16.64B 15.15B 28.57B 1,939B 28.71B 200B 78.35B 987B 75.27B 73.62B 3,172B 12.38B 11.05B 10.27B 9.35B 17.64B 1,197B 17.72B 124B 48.37B 610B 46.47B 45.45B 1,958B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
09/10/26 SEK 1,591.50 +1.08% 435,386
08/10/26 SEK 1,574.50 -2.20% 419,438
07/10/26 SEK 1,610.00 +1.67% 374,867
06/10/26 SEK 1,583.50 +1.51% 480,711
05/10/26 SEK 1,560.00 -0.89% 356,679
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
158.77USD
Average target price
209.08USD
Spread / Average Target
+31.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC